

Multicentre study on coaching and point-of-care technologies for patients with myalgic encephalomyelitis/chronic fatigue syndrome

Submission date 19/03/2026	Recruitment status Not yet recruiting	☒ Prospectively registered ☐ Protocol
Registration date 27/03/2026	Overall study status Ongoing	☐ Statistical analysis plan ☐ Results
Last Edited 10/04/2026	Condition category Nervous System Diseases	☐ Individual participant data ☒ Record updated in last year

Plain English summary of protocol

Plain English summary of protocol not provided at time of registration

Contact information

Type(s)

Principal investigator

Contact name

Prof François-Jérôme Authier

ORCID ID

<https://orcid.org/0000-0002-0182-2052>

Contact details

IMRB Eq. Relaix, Faculty of Medicine, 8 rue du Général Sarrail
Créteil
France
94000
+33 1 4981 2735
francois-jerome.authier@aphp.fr

Type(s)

Scientific

Contact name

Dr Luis Nacul

ORCID ID

<https://orcid.org/0000-0003-1411-8088>

Contact details

The University of British Columbia 6200 University Blvd
Vancouver, BC
Canada
V6T 1Z4
+1 2368631901
luis.nacul@ubc.ca

Type(s)

Scientific

Contact name

Dr Luca Francioso

ORCID ID

<https://orcid.org/0000-0002-4500-0421>

Contact details

Via Monteroni, University Campus Bld. A/3
Lecce
Italy
73100
+39832422525
lucanunzio.francioso@cnr.it

Type(s)

Public

Contact name

Dr Modra Murovska

ORCID ID

<https://orcid.org/0000-0003-0971-1784>

Contact details

16 Dzirciema str
Riga
Latvia
LV-1007
+371 29218082
Modra.Murovska@rsu.lv

Type(s)

Scientific

Contact name

None Diana Arāja

ORCID ID

<https://orcid.org/0000-0002-4558-0980>

Contact details

Riga Stradins University, Dzirciema Street 16
Riga
Latvia
LV-1007
+371 29 129 874
diana.araja@rsu.lv

Type(s)

Scientific

Contact name

None Dita Pole

Contact details

Riga Stradins University, Dzirciema Street 16
Riga
Latvia
LV-1007
+371 22 184 451
dita.pole@rsu.lv

Additional identifiers

EU Horizon Europe Research and Innovation Programme
GA N° 101095654

Latvian Council of Science (Latvijas Zinātnes Padome)
THCS2025-404

Study information**Scientific Title**

Multicentre study of the effectiveness of multimodal coaching interventions and the feasibility of point-of-care test device for improving the quality of life, functional capacity, and self-management in patients with myalgic encephalomyelitis/chronic fatigue syndrome

Study objectives

To evaluate the effectiveness and feasibility of multi-modal coaching interventions and point-of-care test (PoCT) device use in improving the quality of life, functional capacity, and self-management in patients with ME/CFS.

Ethics approval required

Ethics approval required

Ethics approval(s)

Not yet submitted

Primary study design

Interventional

Allocation

Randomized controlled trial

Masking

Open (masking not used)

Control

Active

Assignment

Parallel

Purpose

Device feasibility, Health services research, Supportive care, Treatment

Study type(s)

Health condition(s) or problem(s) studied

Improving the quality of life of patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)

Interventions

Study Methodology and Interventions

This is a multicentre, mixed-design interventional study consisting of three study arms evaluating multimodal coaching interventions and the feasibility of a point-of-care testing (PoCT) device in patients with ME/CFS.

Randomisation

A stratified randomisation approach will be applied in Arm 1 to ensure balanced allocation by country and relevant baseline characteristics (e.g., disease severity). Participants will be randomly assigned in a 1:1 ratio to intervention or control groups within each stratum. Arms 2 and 3 are designed as non-randomised interventional and feasibility studies, due to their exploratory and pilot nature.

Arm 1: Individual Coaching Intervention (Randomised Controlled Study)

Design: Stratified randomised controlled study (1:1 allocation)

Sites: Latvia (LV), France (FR)

Intervention groups:

- Latvia (n=30): Individual health coaching for 12 weeks
- France (n=30): Individual occupational coaching for 12 weeks

Control groups:

- Latvia (n=30): Usual care
- France (n=30): Usual care

Intervention description:

Participants in the intervention groups will receive structured, individual coaching sessions focusing on health management (LV) or occupational functioning (FR). Sessions will be delivered weekly or bi-weekly using standardized protocols.

Duration per participant:

- Intervention: 12 weeks
- Follow-up: 3 months post-intervention

Arm 2: Group Coaching and Education (Pilot + Multicentre Implementation)

Design: Non-randomised pilot followed by multicentre implementation

Sites: Canada (pilot), Latvia, France

Pilot phase:

- Canada (n=40): Group-based coaching and education programme (15 months total duration, including development and testing phase)

Implementation phase:

- Latvia (n=20) and France (n=20): Group coaching and education programme

Intervention description:

Participants will engage in structured group sessions focusing on patient education, self-management strategies, and peer support.

Duration per participant:

- Intervention: 3 months
- Follow-up: 3 months post-intervention

Arm 3: PoCT Device Feasibility and Usability Study

Design: Non-randomised feasibility study

Sites: Italy (development and initial testing), Latvia

Development phase:

- Italy: PoCT device development and pre-clinical validation (12 months)

Clinical testing phase:

- Italy (n=30): PoCT testing (5 months)
- Latvia (n=30): PoCT testing (5 months)

Intervention description:

Participants will undergo testing with a point-of-care device measuring inflammatory cytokines and lactate in peripheral blood. Results will be compared with standard laboratory methods and correlated with clinical outcomes.

Duration per participant:

- Active testing: up to 5 months
- Follow-up: included within study assessments

Overall Study Duration

The total study duration across all arms is 22 months, including intervention and follow-up phases.

Intervention Type

Mixed

Primary outcome(s)

1. Health-related quality of life (HRQoL) measured using SF-36, ED-5D-5L and EQ-VAS at baseline and post-intervention (12 weeks), with a follow-up at 3-6 months post-trial

Key secondary outcome(s)

Completion date

31/08/2028

Eligibility

Key inclusion criteria

1. Age 18-75 years
2. Diagnosis of ME/CFS according to International Consensus Criteria (ICC), or Canadian Consensus Criteria (CCC), or Institute of Medicine/National Academy of Medicine (IOM/NAM) criteria, or National Institute for Health and Care Excellence (NICE) criteria
3. Mild, moderate or severe functional impairment (e.g., ≥ 4 Bell Disability Scale ≤ 70)
4. Capacity to provide Informed Consent

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

18 Years

Upper age limit

75 Years

Sex

All

Total final enrolment

0

Key exclusion criteria

1. Primary psychiatric disorders (e.g., schizophrenia, bipolar disorder)
2. Severe comorbidities that interfere with participation
3. Current participation in another interventional trial

Date of first enrolment

01/09/2026

Date of final enrolment

29/02/2028

Locations

Countries of recruitment

Canada

France

Italy

Latvia

Sponsor information

Organisation

Université Paris-Est Créteil

ROR

<https://ror.org/05ggc9x40>

Organisation

University of British Columbia

ROR

<https://ror.org/03rmrcq20>

Organisation

Institute for Microelectronics and Microsystems

ROR

<https://ror.org/05vk2g845>

Organisation

Riga Stradiņš University

ROR

<https://ror.org/03nadks56>

Funder(s)

Funder type

Funder Name

Agence Nationale de la Recherche

Alternative Name(s)

French National Research Agency, French National Agency for Research, AgenceRecherche, ANR (Agence nationale de la recherche), L'Agence nationale de la recherche, National Agency for Research, L'Agence nationale de la recherche (ANR), ANR

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

France

Funder Name

Canadian Institutes of Health Research

Alternative Name(s)

Instituts de Recherche en Santé du Canada, The Canadian Institutes of Health Research (CIHR), Canadian Institutes of Health Research (CIHR), Canadian Institutes of Health Research | Ottawa ON, CIHR - Welcome to the Canadian Institutes of Health Research, CIHR, IRSC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

Canada

Funder Name

Ministero dell'Università e della Ricerca

Alternative Name(s)

Ministry for Universities and Research, Italy, MUR Ministero dell'Università e della Ricerca, Ministry for Universities and Research, Ministero Università e Ricerca, Italian Ministero Università e Ricerca, MUR, M.U.R.

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

Italy

Funder Name

Latvijas Zinātnes Padome

Alternative Name(s)

Latvian Council of Science

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

Latvia

Funder Name

HORIZON EUROPE Reforming and enhancing the European Research and Innovation system

Alternative Name(s)

Reforming and enhancing the European Research and Innovation system, Reforming and Enhancing the European R&I System, Reforming and enhancing the EU research and innovation system, Reform and Enhance the EU R&I system, Reform und Verbesserung des europäischen Forschungs- und Innovationssystems, Reformar y mejorar el sistema europeo de investigación e innovación, Reforma a posílení evropského systému výzkumu a inovací, Réformer et renforcer le système européen de recherche et d'innovation, REERIS

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Not expected to be made available